📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
0 articles
AVG GRADE
—
SENTIMENT
NEUTRAL
TOTAL VIEWS
0
RECENT COVERAGE · 2 ARTICLES
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO)
Spero Therapeutics (SPRO) experienced a notable selloff following FDA approval of Utebzi, despite the regulatory win appearing...
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
SPRO achieved a significant regulatory milestone with FDA approval of Utebzi, the first and only oral carbapenem antibiotic for...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice